ARCH Venture Partners

US biotech VC

Explore the full dataset

2018 YTD investments

Company name Date Series Deal amount ($M) Therapeutic area Stage Role
Scholar Rock 01/03/2018 Series C $47

Oncology

Rare disease

Preclinical Existing investor
Gossamer Bio 01/05/2018 Series A $100

Undisclosed

Phase 2 Lead investor
Unity Biotechnology 03/19/2018 Series C $55

Aging

Phase 1 Existing investor
Hua Medicine 03/27/2018 Series D + E $117

Diabetes

Phase 3 Existing investor
insitro 05/02/2018 Series A Undisclosed

Undisclosed

Preclinical Lead investor
Cstone Pharmaceuticals 05/10/2018 Series B $260

Oncology

Phase 1/2 New non-lead investor
Beam Therapeutics 05/14/2018 Series A $87

Undisclosed

Preclinical Lead investor
Nohla Therapeutics 05/16/2018 Series B $45

Hematology

Oncology

Phase 2 Existing investor
Brii Bio 05/24/2018 Series A $260

Undisclosed

Undisclosed Lead investor
Metacrine 06/06/2018 Series C $65

Liver disease

Gastrointestinal disease

Metabolic disorders

Phase 1 Existing investor
Hangzhou Just Biotherapeutics 06/06/2018 Series B $35

Oncology

Rare disease

Metabolic disorders

Preclinical Existing investor
Gossamer Bio 07/23/2018 Series B $230

Undisclosed

Phase 2 Existing investor
Omniome 07/30/2018 Series B $60 None Existing investor
Karuna Pharmaceuticals 08/02/2018 Series A $42

Neurology

Pain

Alzheimer's disease

Phase 2 Lead investor
Magnolia Neurosciences 08/13/2018 Series A $31

Alzheimer's disease

Neurodegenerative

Preclinical New non-lead investor
OncoResponse 09/11/2018 Series B $40

Oncology

Preclinical Existing investor
KSQ Therapeutics 09/28/2018 Series C $80

Oncology

Autoimmune

Rare disease

Preclinical Existing investor
Glympse Bio 10/09/2018 Series A $22

Liver disease

Preclinical Lead investor

2018 YTD exits: this feature is in beta, data may be incomplete


IPOs

Company Date Amount ($M) Post-money ($M) Therapeutic area
Homology Medicines 03/27/2018 $144.0 $598.9

Oncology

Rare disease